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1. Introduction
Autoimmune diseases are systemic and organ–specific inflammatory conditions involving a
cell-mediated immune response against self tissues. Whilst it is known that they are charac‐
terized by autoantibodies in both the systemic fluid and tissues [1, 2], the detailed aetiology
and pathogenesis of auto-immune diseases are still poorly understood [3, 4]. These types of
diseases occur when self molecules, often unknown antigens (auto-antigens), are seen by the
immune system as non-self and are thereby attacked immunologically by the production of
autoantibodies against them. In this process, the immune system mistakenly reacts with the
body’s own cellular gears as if they were foreign antigens. The clinical presentations of auto-
immune diseases vary with the disease course and delay in diagnosis as well as inappropri‐
ate therapy, increases tissue damage [3, 5].
Inflammatory arthritis  (IA),  an autoimmune disorder  of  the joint  tissue,  is  characterised
by influx of white blood cells in the joint fluid. The disease often progresses to articular
destruction,  joint  ankylosis  (stiffness  of  the  joint)  and  functional  disability  [3].  IA  is  a
chronic disease, persisting as it often does for a long time, and some forms of the condi‐
tion are systemic affecting many tissues and organs other than the joint and skin. IA is a
significant cause of disability in those over fifty-five years of age, and is among the lead‐
ing  conditions  restricting  an  individual’s  capacity  to  work.  The  healthcare,  socio-  and
pharmaco-economic  challenges  of  IA  are  significant.  The  most  important  issues  for
healthcare include: i) recognition and establishing an early diagnosis for disease; ii) iden‐
tification of patients who are likely to develop a worse prognosis; iii)  predicting and se‐
lecting  therapies  to  which  patients  will  respond;  and,  iv)  understanding  the  balance
between limited healthcare resources and the expensive disease modifying anti-rheumatic
drugs (DMARDs) [3].
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There has been much excitement about the potential of the omics technologies to deliver novel
biological markers (biomarkers) of sufficient discriminatory power that they could herald an
era of personalised medicine [6]. Personalized medicine being a medical approach that custom‐
izes healthcare; tailoring decision to individual patients based on genetic, proteomic or other
information. Accurate prediction is essential for personalized medicine to ensure that therapy
is given to those individuals who are likely to develop worse prognosis [7]. More specifically,
the application of proteomics (the study of proteins), has been suggested to hold special prom‐
ise for the discovery of clinically useful biomarkers [6, 8]. Biomarkers are characteristics that
can be measured or evaluated to indicate a normal biologic process, a patho-physiologic condi‐
tion, or a pharmacologic response to therapy. Biomarkers are also defined as measurable varia‐
bles of how a patient feels or functions. [9, 10]. Proteomics is extremely powerful for both
biomarker discovery and for the investigation of biochemical processes involved in diseases.
At its most straightforward, proteomics involves the comprehensive determination of protein
expression levels and hence enables pathway determination of cellular processes [11]. Several
proteomic approaches have been applied to the investigation of autoimmune disorders includ‐
ing (i) autoantigen and biomarker discovery by 2-dimensional gel electrophoresis (2-DE) based
separation of proteins and subsequent protein identification by mass spectrometry; (ii) protein
microarrays for the characterisation of antibody responses; (iii) reverse phase protein arrays to
analyze protein phosphorylation (iv) antibody array technologies to profile cytokines and oth‐
er biomolecules; and (v) flow cytometric analysis of phosphoproteins [2, 3].
Here we review the role of autoimmunity in IA with emphasis on disease aetiology, patho‐
genesis, existing biomarkers, assessment of disease activity, autoantibodies capable of pre‐
dicting disease outcomes and latest therapies. We then outline the application of proteomics
to the discovery of protein biomarkers in rheumatoid arthritis. The processes and challenges
involved in validating potential biomarkers and developing them to laboratory tests of clini‐
cal utility are also summarised. Finally, we discuss some future directions in protein bio‐
marker research in IA that may support personalised medicine for this autoimmune disease.
1.1. Inflammatory arthritis: An autoimmune disorder
Inflammatory arthritis is an autoimmune disease; it has the characteristic hallmark of acti‐
vated immune cells that target self tissues. This auto-immunity is always as a result of com‐
plex interaction between genetic and environmental factors [3]. There are several forms of
IA including rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis
(JIA), ankylosing spondylitis (SpA) as well as the inflammatory form of osteoarthritis (OA).
Cells involved in autoimmune IA include macrophages, T cells, B cells, fibroblasts, chondro‐
cytes, and dendritic cells. It is known that the expression of key cytokines such as tumor ne‐
crosis factor alpha (TNF-α) and interleukin-6 (IL-6) drives the inflammatory and destructive
processes. TNF-α is a pro-inflammatory cytokine that is associated with fever and some oth‐
er symptoms such as pain, tenderness and swelling, in several inflammatory conditions and
over recent years has been a major target of treatment for IA [12].
In this review, emphasis is placed on RA, the most common form of IA. With its course clinical‐
ly unpredictable, RA is associated with synovial inflammation in which the synovium, a thin
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layer of tissue that lines the joint cavity, is the primary site of the cell-mediated inflammatory
reaction [13]. RA has a very poor prognosis when compared to entheseal-based inflammatory
conditions such as spondyloarthropathy where the entheses - the site where tendons, joint cap‐
sules or ligaments insert into bone – are inflamed [14]. RA is often characterised by chronic in‐
flammation of the joint that has been infiltrated by activated mononuclear cells. Inflammation
is usually accompanied with swelling, pain and the destruction of articular cartilage, which ul‐
timately lead to functional impairment of the affected joint [5, 15]. RA can hence be classified as
an heterogeneous disease due to its different forms of clinical manifestations, serological ab‐
normalities, functional impairment and joint damage [16, 17]. It has been reported that early
and aggressive treatment of RA can prevent cartilage damage [3]. Before the introduction of
‘biologic’ therapies, the direct and indirect costs incurred for medical, social care and loss of
employment experienced by RA patients and society at large were estimated to be $98 million
to $122 million per million population in developed countries [18, 19].
1.2. The aetiology / pathogenesis of rheumatoid arthritis
The synovial membrane is the thin layer that lines the joint. It produces synovial fluid, which
nourishes and lubricates the joint. Two cell types characterise the synovial membrane: macro‐
phage–like and fibroblast-like synoviocytes. Although the pathogenesis and the aetiology of
RA remain unclear, it is sometimes associated with genetic and environmental factors. Envi‐
ronmental factors associated with RA include cigarette smoking, alcohol, some reproductive
factors in women, bacterial products, viral components and some other diverse environmental
stimuli [12, 20]; the genetic factors are linked to the class 11 major histocompatibility complex
(MHC) region on chromosome 6 and an association with the non-MHC gene (PTPN22-a pro‐
tein tyrosine phosphatase that regulates T cell activation). Additionally, predisposing genes
such as the HLA-DR4 allele are reported to be prevalent [18, 21]. Innate immunity is a primitive
pattern-recognition system that leads to rapid inflammatory responses. In RA, innate immuni‐
ty has been implicated through the engagement of Fc receptors by immune complexes and per‐
haps  Toll-like  receptors  (TLRs)  by  bacterial  products.  Antigen-driven  T  cell  and  B  cell
responses may also participate as a result of either xenoantigen reactivity or, more likely, re‐
sponses directed at numerous autoantigens. Evidence of autoimmunity, including high serum
levels of autoantibodies such as rheumatoid factor (an antibody against the Fc region of other
antibodies) and anti-citrullinated peptide antibodies, can be present for many years before the
onset of clinical arthritis [20]. In some patients, worse prognosis of RA has been linked to the
presence of rheumatoid factor and anti-CCP (antibody against citrullinated epitopes on post-
translationally modified proteins). The proliferation of synoviocytes as RA progresses leads to
the invasion of the hyperplastic synovial tissue and is responsible for the destruction of the un‐
derlying bone and the articular cartilage [21]. Cytokines and chemokines play an essential role
in the angiogenesis and pathogenesis of RA [22, 23]. The expression of cytokines such as tu‐
mour necrosis factor-α (TNFα), interleukin (IL)-1β, IL-6, IL-15 and IL-17 during new blood ves‐
sel formation (angiogenesis) and inflammatory cell infiltration drives the inflammatory and
destructive processes of this disease [21, 23]. The clinical presentation of RA differs from other
forms of arthropathies with its characteristic symmetric polyarticular joint inflammation and
destruction as well as its extra-articular manifestation (rheumatoid nodules/vasculitis) and the
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presence of intracellular citrullinated proteins. The synovial membrane is affected in a number
of ways which include architectural changes (neovascularisation, lymphocyte infiltration and
thickening of the synovial lining layer) [23, 24]. Cardiovascular diseases, excess morbidity and
mortality from myocardial infarction and allied disorders, high risk of lung diseases, coronary
artery disease, lymphoma, infection as well as reduced life expectancy are associated with
rheumatoid arthritis [16].
A model has suggested that in predisposed individuals, a stimulus or an infective agent binds
to toll-like receptors on macrophages and peripheral dendritic cells; thereby triggering a rapid
response from the innate immune system involving inflammatory mediators, cytokines, com‐
plements, neutrophils and natural killer cells. The migration of these cells to the joint leads to
joint damage as a result of the actions of growth factors, proteases and activated osteoclasts.
This damage is associated with the development of locally invasive pannus tissue [18]. The ma‐
jor joint destruction occurs at the pannus; this is the point at which the synovium meets the car‐
tilage and the bone. The pannus is rich in macrophages and it is the major site at which
irreversible tissue damage originates [25, 26]. The main cause of disability in RA is joint de‐
struction that is characterised by progressive bone erosion [18]. As shown in Figure 1 below, in‐
filtration of the joint by macrophages ultimately form the pannus that migrates into the bone
leading to bone erosion. The inflamed joint compared to the normal joint is characterised by the
influx of a number of inflammatory cells in the joint.
Figure 1. Normal healthy joint (a) and rheumatoid arthritic joint (b). [21]
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In the healthy joint (a), a thin synovial membrane lines the non-weight-bearing aspects of
the joint. While in the arthritic joint (b), the synovial membrane becomes hyperplastic and
infiltrated by chronic inflammatory cells that develops into ‘pannus’, which migrates onto
and into the articular cartilage and underlying bone causing bone erosion.
1.3. Current therapeutic targets and therapy in RA
Cytokine networks involving tumor necrosis factor, interleukin-6, and many other factors
participate in disease perpetuation and can be targeted by therapeutic agents [20]. Disease-
modifying antirheumatic drugs (DMARDs) have been used for decades to manage rheumat‐
ic diseases. Methotrexate is the most widely used disease DMARD. Other DMARDS include
leflunomide, sulfasalazine, cyclosporine and hydroxy-chloroquine (20). However, in the
past decade, biologic therapies such as fusion proteins and monoclonal antibodies have rev‐
olutionized the management of autoimmune IA. Biologics have provided more specific ther‐
apeutic interventions with less immunosuppression by targeting immune cells and key
cytokines [21]. The biologicals neutralize the actions of cytokines and proteins through hu‐
man or chimeric monoclonal antibodies or by using a recombinant-antagonist form of the
cytokine receptor [14, 27]. Example of such biologicals is the TNF-α inhibitors. TNF-α being
a key component in the cascade of cytokines induced in RA, is a target compound for treat‐
ment. To exert its effects, TNF-α bind to two receptors, the type 1 TNF receptor (p55) and
the type 2 TNF receptor (p75), found on immune, inflammatory, and endothelial cells. TNF
inhibitors were first licensed for clinical use in 1998; three have been approved for the treat‐
ment of RA. TNF inhibitors are introduced to patients with active disease who have not had
a response to conventional DMARDs. Examples of the monoclonal antibodies include inflix‐
imab (Remicade), a chimeric human-murine IgG1 anti-TNF-α antibody administered intra‐
venously. Infliximab is also cytotoxic for TNF-expressing cells; adalimumab (Humira) or
certolizumab pegol (Cimzia). Humira is a recombinant humanized monoclonal anti-TNF-α
antibody administered subcutaneously. There are also circulating receptor fusion proteins
such as etanercept (Enbrel), a recombinant soluble p75 TNF- receptor fusion protein admin‐
istered subcutaneously [18]. By inhibiting the action of TNF-α, the ‘biologicals’ reduce the
signs and symptoms of inflammation and stop the progression of joint damage. Therapeutic
response in RA is assessed by clinical disease activity score 28 (DAS28) or ACR (American
College of Rheumatology) criteria, structural (sharp or Larsen scores) and or functional eval‐
uation standards (HAQ score). Treatment efficacy is usually estimated by comparing these
assessments before and after treatment [27].
1.4. Disease activity and progression in RA
The terms ‘activity’ and ‘severity’ are usually used to characterize RA. Disease activity in
this  sense refers  to  the degree of  overall  inflammation measured by considering factors
that  include  acute  phase  reactants,  tender/swollen  joints,  pain,  general  impact,  grip,
strength and functional  disability.  Disease  severity  on the  other  hand,  is  more  complex
as it refers to the outcome or result of RA. Disease severity is measured by assessing ra‐
diographic  abnormalities,  indirect  and direct  costs,  work disability,  mortality  and social
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losses;  generally elucidate  the extent  the disease has affected the patient  and its  effects.
Severity explains the absolute social  and physical  damage resulting from RA as well  as
the rate at which the damage occurs [28,  29].  Informative characteristics for clinical out‐
comes can be broadly divided into prognostic  or  predictive  biomarkers.  Prognostic  bio‐
markers  show the  expected  clinical  outcomes  of  patients  such  as  progression  or  death.
However,  they do not  inform the  choice  of  therapy while  predictive  biomarkers  would
identify group of patients whose diseases are likely to be resistance or sensitive to thera‐
py based on the biomarker status [30].
2. Assessment of disease activity and response criteria in RA
In practice today, the European League Against Rheumatism (EULAR) criteria are used to
classify the disease activity in IA while the American College of Rheumatology (ACR) im‐
provement criteria is the second method used for clinical evaluation of patients [31]. In RA,
inflammatory activities cannot be measured using one single variable. The disease activity
score (DAS) was developed to solve this problem [32]. DAS score provides important quan‐
titative analysis in clinical research of RA and the score includes tender joint count, swollen
joint count, C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) level and the
general assessment of the patient’s health measured on a visual analog scale. At baseline
and follow up, responses to treatment are assessed as low, moderate or high disease activity.
DAS is best defined by statistical methods which include multiple regression analysis and
discriminant analysis [31, 33]. A low disease activity is indicated by a DAS score <3.2, a
moderate disease activity is indicated by DAS score 3.2- 5.1 while a DAS score >5.1 indicates
a high disease activity [34]. These criteria are being used by the EULAR to define good res‐
ponders, moderate responders and non responders to treatment as shown in Table 1 below.
Advantages of the DAS include the following: its content is more informative than single
variables, its values can be interpreted clinically and it has a continuous scale with a Guassi‐






DAS Improvement from Baseline
>1.2 >0.6≤1.2 ≤0.6
‘Low’ ≤3.2 Good responce Moderate responce No responce
‘Moderate’ >3.2≤5.1 Moderate Moderate None
‘High’ >5.1 Moderate None None
Table 1. The EULAR response criteria [32]
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The ACR improvement criteria are used in clinical trials for the evaluation of RA patients. It
is also referred to as the core data set. It involves swollen joint count, tender joint count,
acute phase reactants i.e. ESR/CRP and the general health assessment questionnaire (HAQ
score). The questionnaire assesses the pain, disability, and overall health of the patient. The
ACR measures improvement in percentage of the changes in the criteria scales used. 20%,
50% and 70% improvement in any 4-6 of the scale used is an indication that the patient
meets the criteria [34].
2.1. Clinical and biological markers used in practice for RA
Clinically meaningful biomarkers may be based on proteins,  genotypes,  histology, meta‐
bolic  patterns,  or  imaging techniques and they are ideal  for  early diagnosis,  monitoring
and  prediction  of  therapeutic  response.  In  a  number  of  diseases  and  especially  in  RA,
some patients do not respond to therapy at all  and several others show diverse degrees
of response. Therefore, biomarkers are urgently needed in the clinical setting (i) to select
patients before treatment, (ii) to monitor the patients’ response to the therapy as well as
the disease activity, (iii) to classify patients into their different response categories (good
responders,  moderate  responders  and  nonresponders)  and  (iv)  to  determine  the  OBD
(optimal biological dose) for the drug [35-37].
Clinical markers are the physical symptoms or variables such as swollen joint count, tender
joint count, pain assessment and radiological findings while biomarkers are molecular indi‐
cators of pathological processes as described earlier to assess diagnostic, prognostic and pre‐
dictive features [38]. Biomarkers of RA can be broadly divided into two groups: Biomarkers
of disease activity and biomarkers of joint damage.
Biomarkers of  disease activity in RA are also referred to as ‘momentary predictors’  and
include  factors  that  change  with  time  revealing  the  disease  activity  e.g.  ESR  and  CRP
[19].  Biomarkers  of  disease  activity  include  cells,  cytokines  and  acute  phase  reactants/
proteins. Cells involved in RA synovitis exhibit increased number of macrophages in the
synovium. B-cell depletion and the serum level of proinflammatory cytokines (IL-6 being
the most abundant cytokine) can give the reflection of active disease. High Composition
of  synovial  tumour necrosis  factor  (TNF) is  also a  biomarker  of  RA.  Serum amyloid A,
an acute phase protein,  blood sedimentation rate as well  as the presence of  rheumatoid
factor (RF) also reflects disease activity; as this can be used to calculate the disease activi‐
ty score 28 (DAS28 i.e. 28 joint counts) [5, 17]. CRP, an acute phase protein has been suc‐
cessful  to  some  extent  to  monitor  early  stage  disease  and  progression  after  the
commencement  of  therapy.  CRP can be  alternatively  measured by calculating ESR [21].
However,  some other  factors  have  been  found to  influence  the  levels  of  both  ESR and
CRP  rendering  these  as  non–specific  markers;  these  factors  include  anemia,  aging  and
the presence of immunoglobulin such as rheumatoid factor [9]. Studies have shown CRP
as a marker of different inflammatory disease activity [39]. As momentary predictors re‐
veal outcomes, they require re-sampling to boost the accuracy [28].
Biomarkers of joint damage in RA are also referred to as ‘cumulative predictors’ and their
outcomes are variable and worsen with time. These include radiographic erosion and func‐
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tional disability [28]. In RA, changes in bone and cartilage lead to joint damage. Spaces in
the joint signify cartilage changes while erosion indicates bone destruction. Hence, either of
these two changes can present a biomarker of RA joint destruction. Cartilage damage causes
a change in the matrix composition of the cartilage thereby affecting the major proteins in
cartilage: type 11 collagen (COL 2), aggrecan, and non-collagen and non-aggrecan proteins.
The main structural protein in bone is the type 1 collagen and the non collagen protein in
bone is the sialoprotein which is released during bone damage [17].
Some RA patients with active disease present with normal levels of some of these mark‐
ers;  this  might be due in parts to genetics [40].  Due to lack of  specificity,  such markers
might not  be good for all  RA patients;  hence,  a  need for better  biomarkers.  The under‐
standing derived from the disease biology has shifted the treatment strategy to targeted
therapy.  However,  to  develop,  verify,  validate  and  apply  new  and  existing  treatment
successfully, there is a need to understand the difference and relationship between puta‐
tive biomarker and treatment effect [30].
Notably, to date, there is no effective approach available to clinicians to predict which pa‐
tient will respond to which therapy. For example, predicting which patients are likely to re‐
spond to TNF-α inhibitors would have significant value for the selection of patients whose
condition warrants this high cost and ‘high risk’ treatment [41].Therefore, there is an urgent
need for new and better biomarkers in IA to improve diagnosis, support emerging targeted
therapies, monitor drug activity and evaluate therapeutic response [1, 3].
In RA, any indicator of inflammation could be a biomarker [5]. These may include genes or
products of gene expression, a cytokine, autoantibody, some acute phase proteins, tissue
degradation product or tissue abnormality observed immunohistochemically in synovial bi‐
opsy. Sources of these biomarkers may include the serum, synovial fluid, urine, cells (lym‐
phocytes such as the peripheral blood mononuclear cells (PBMC)) and tissues taken from
the inflamed synovium [17]. RA biomarkers effectively used in practice are acute phase reac‐
tants (CRP and ESR) as well as autoantibodies Such as rheumatoid factor (RF), anti citrulli‐
nated protein antibodies (ACPAs) and anti-nuclear antibodies (ANA). These autoantibodies
are capable of predicting disease outcomes and are used as laboratory markers to classify
and diagnose RA. Autoantibodies are dependent on the organ or tissue affected as well as
the severity of the disease. [42-44]. Highlighted below are the markers used in clinical prac‐
tice for the diagnosis and prognosis of RA:
• Rheumatoid factor (RF): These are antibodies against the Fc region of other antibodies
[21]. This IgM isotype of the serologic indicator of RA is useful in determining the auto
immune status of the disease but it is not very sensitive to the changes in the disease ac‐
tivity level or specific as it could be present in patients with chronic infections, other im‐
mune diseases or in the elderly. The main use of which is a prognostic marker [45, 46]. RF
predicts disease severity but it is not a good marker for early diagnosis. It is not very sen‐
sitive and does not vary stoichiometrically with treatment [29].
• C-reactive protein (CRP): RA increases the level of an acute phase reactant, CRP. This
is a typical marker of inflammation and it has an association with cardiovascular risk
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[16].  CRP  is  a  plasma  protein  used  for  drug  dosage  titration  as  well  as  clinical  re‐
sponse assessment [47]. Although CRP is a widely used biomarker of RA, it lacks dis‐
ease  selectivity  [48].  CRP  correlates  with  disease  activity  but  does  not  predict  the
severity of the disease [29].
• Erythrocyte sedimentation rate (ESR): This contributes highly to disease activity but it is
not a sensitive parameter and it can be easily affected by external factors such as age, fi‐
brinogen level, gender, hypergamma-globulinemia, anaemia and RF [48]. Like CRP, it
does not predict the subsequent severity of the disease [29].
• Anti-citrullinated protein antibody (tested as anti-cyclic citrullinated peptide (Anti-CCP)
antibody): Recently, anti-CCP antibody has been effectively used for the diagnosis of RA
[43, 47]. ACPAs are circulating autoantibodies against citrullinated epitopes on post trans‐
lationally modified proteins. Citrulline is a non standard amino acid that originates from
the enzymatic modification of deiminated arginine residue [46]. The citrullination/modifi‐
cation of arginine by deimination occurs physiologically during inflammation, apoptosis
or keratinization. These proteins can be found either in the sera or in the synovium of RA
patients. The presence of citrullinated proteins are associated with a worse prognosis of
RA[21]. ACPAs are markers of RA with a specificity of 95-98% and a sensitivity of 70-80%
[49]. As a result of their excellent diagnostic value, they are a better alternative to RF and
they are widely used for the diagnosis of RA [45, 46]. The presence of this autoantibody in
the serum precedes the onset of the disease and also linked to the pathogenesis of the dis‐
ease. The isotypes of this antibody includes IgA, IgG1, IgG2, IgG3, IgG4 and IgM [45, 49].
Anti-keratin antibodies (AKA) and anti-perinuclear factor (APF) are examples of mem‐
bers of ACPAs. An example of anticitrullinated antibodies that has been detected in the
sera of RA patients is the antibody against citrullinated vimentin. Vimentin, a protein that
plays vital biologic role in contraction, proliferation and migration has also been found to
be highly expressed in RA [24]. The mutated form of this antibody was recently devel‐
oped and it is known as anti-MCV antibody. The sensitivity of which is comparable to RF
but no greater specificity [45, 46]. These antibodies alone or in combination with IL-6 have
a high classification power for the establishment of RA [50]. These antibodies have recent‐
ly predicted erosion. They are usually associated with high titre rheumatic factor;
i.e≥50IU/ml. These antibodies and the presence of acute phase proteins are reliable to pre‐
dict erosive RA. Anti-nuclear antibody (ANA) is also used for the diagnosis of arthritis
and can be used to differentiate different forms of inflammatory arthritis [5].
2.2. Emerging potential biomarkers in RA
To demonstrate efficacy and define appropriate RA patients in clinical trials, the identifica‐
tion of easily measured, rugged, reliable markers of disease and the effects of drugs are criti‐
cal and emerging [51]. Different research works are ongoing to reveal emerging and
interesting biomarkers. During biomarker identification, attention needs to be paid to the se‐
lection of the biological matrix in which the particular biomarker level will be monitored
keeping in mind the feasibility of sample collection from such matrix, the stability of analyte
in such matrix, assay sensitivity requirement based on the anticipated biomarker level in
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such matrix as well as the relevance of the matrix to biology. Biomarkers that will be trans‐
latable from bench to bedside will have to be accessible with minimal invasive procedure.
Plasma and serum are the most easily accessible body fluids. In addition to this however,
there should be a link between the matrix and the originating tissue source for biomarkers
measured in body fluids [52]. The synovial fluid is a good source of novel biomarkers for
many arthritic diseases that involve joint inflammation [53]. However, any measure used as
a biomarker has to be evaluated and validated to ensure that the laboratory test is accurate,
specific, sensitive and reproducible. The emerging RA biomarkers may be used to subgroup,
treat and monitor the treatment [17]. The focus here is on a group of protein biomarkers
characterized by a known molecular structure or formula or heterogeneous proteins with or
without posttranslational modifications and some cytokines. This does not include image
measurement, cell type, count, activity, or behavioural models. Novel techniques are emerg‐
ing to discover protein biomarkers of inflammatory arthritis [28, 29].
2.2.1. Emerging biomarkers from the serum
Emerging serum markers include circulating autoantibodies against citrullinated proteins.
These have high selectivity and specificity for the early diagnosis of RA [54].
• Matrix metalloproteinase 1 (MMP-1) and tissue inhibitor of metalloproteinase 1 (TIMP-1):
These are tissue destructive enzymes [21]. Murphy et al, found an association between
elevated levels of MMP-1 in blood and synovial tissue of RA patients and formation of
new erosion [55].
• Myeloid –related proteins/Pro-inflammatory cytokines: The innate immune system of the
bone activates macrophages on recognition of invading microorganisms. This activation
occurs by pathogen associated molecular patterns (PAMPs) and by reacting to tissue
damage recognised as damage associated molecular patterns (DAMPs). Prominent pro‐
teins released by activated macrophages include calgranulins, myeloid related proteins
MRP8 (S100A8) and MRP14 (S100A9). These S100 protein families are calcium binding
proteins that induce pro-inflammatory responses in leucocytes and endothelial cells [56].
The pro-inflammatory cytokines include interleukins (IL-1β, IL-6, IL-15 and IL-17) and tu‐
mour necrosis factor-α (TNF-α) [5, 21]. A correlation exists between IL-6 and acute phase
proteins; therefore IL-6 can be used to monitor disease activity in RA. However, due to its
diurnal variability (variable concentrations in the morning and in the evening), it is not a
reliable marker [48]. Macrophages are stimulated by inflammatory mediators such as in‐
terleukin (IL 1), tumour necrosis factor (TNF-α) or interferon (IFN) to secrete and up reg‐
ulate myeloid- related proteins [56]. Serum amyloid protein A (SAA), is also an emerging
biomarker of RA [57].
According to previous work from peripheral blood mononuclear cells, swiprosin 1, the ez‐
rinmoesin binding protein EBP50, and non-muscle actin have been shown to be differential‐
ly expressed in RA. Additionally, GRP78 a glucose regulated protein and the heat shock
protein HSP60 have been identified as major auto-antigens in RA., GRP78 has been suggest‐
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ed as an immunotherapeutic agent for the treatment of arthritis and targeting HSP60 is said
to be beneficial for the treatment [5].
2.2.2. Emerging biomarkers from the synovial fluid
Calprotectin, a major leucocyte protein has been found in high concentration in the synovial
fluid of RA patients. It is a calcium binding pro inflammatory S100 protein (S100A8/
S100A9). It is also known as MRP-8/MRP14; calgranulin A/calgranulin B or cystic fibrosis
antigen [58]. S100A8 (MRP-8/calgranulin A), S100A9 (MRP-14/calgranulin B) and S100A12
(calgranulin C) proteins have been found to be the most up-regulated proteins in the synovi‐
al fluid of RA patients. Although present in the serum of RA Patients, these proteins are pre‐
dominant in their synovial fluid. RA can be diagnosed early by the serum expression of
these proteins [24, 59]. In the synovial fluid and the synovial membrane of mononuclear
cells, cytokines such as the IL-18 have been found to be highly expressed and it has also
been found to contribute to inducing high levels of other monocytes such as the IL-6, TNF-α,
IL-1β and the granulocyte-macrophage colony-stimulating factor (GM-CSF) [60]. Pro-in‐
flammatory cytokines such as the IL-1 and TNF-α protein are also readily detectable in the
synovial fluid. Other detected cytokines include the macrophage colony stimulating factor
(M-CSF), leucocyte inhibitory factor (LIF), IL-6 and interferon α (IFNα) [26]. Studies on cit‐
rullinated proteins and autoantibodies in RA synovial fluid are ongoing and emerging; an
example is the fibrinogen-derived endogenous citrullinated peptides [61].
2.2.3. Emerging biomarkers from the bone and cartilage
Abnormal and degraded cartilage in affected joint is one of the major clinical manifestations
in RA. Collagens are markers of bone turnover/resorption. The synthesis and degradation
products of metabolism of cartilage specific collagens and proteoglycans are released into
the synovial fluid, serum and urine as by products. These biomarkers can be used to moni‐
tor the metabolism of the cartilage. The main collagen of the articular cartilage is the type 11
collagen (C11) and it is a major structural component of the tissue. It is excessively degraded
in RA [60]. Cartilage oligomeric matrix protein (COMP) is another marker that has been
shown to provide a measure of elevated cartilage degradation [62]. So pyridinoline and de‐
oxypyridinolin (PYD, DPD) are also specific markers of bone resorption; these are cross-
linking amino acids that strengthen collagen fibrils in the extracellular matrix. PYD and
DPD are found in main fibril – forming collagen 1, 11 &111 of many tissues [63].
2.2.4. Emerging biomarkers from the synovial membrane /tissue
In RA, the synovial membrane of the affected joint is the most affected part and therefore it
is the primary site of inflammation. The number of macrophages in tissue biopsies of RA pa‐
tients has been identified to correlate with the degree of pain. A study into Tcell infiltration
within the synovial membrane during the disease has shown that there is a correlation be‐
tween an improvement in the clinical index of the disease activity and a decrease in Tcell
infiltration. The clinical course of RA and the response to treatments has been found to cor‐
relate with the number of sublining macrophages in the tissue. However, the synovial mem‐
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brane presently does not have a reliable marker for early detection of arthritis but useful for
determining the prognosis of the disease [13]. The synovial biopsies from the synovial tissue
are useful for diagnosis purposes as well as the evaluation of novel treatments [64]. Small
chemoattractant cytokines known as chemokines play a role at the site of inflammation to
accumulate inflammatory cells. The synovial tissue and fluid exhibits an increased concen‐
tration of some chemokines which includes the monocyte chemoattractant protein-4
(MCP-4/CCL13), the monokine induced by interferon-γ (Mig/CXCL9), pulmonary and acti‐
vation-regulated chemokine (PARC/CCL18), the monocyte chemotactic protein 1 (MCP-1/
CCL2), the stromal cell-derived factor-1 (SDF-1/CXCL12) and fractalkine (CXC3CL1). These
chemokines and their receptors are important in the pathology of RA [22]. Studies on the
synovial tissue are ongoing to discover better protein biomarkers from the synovial tissue.
Although not yet validated for use in clinical practice, some proteins from the synovial tis‐
sue such as fibrinogen, annexin, fibronectin, vimentin, haptoglobin, S100A8, S100A10 and
some others are under study for implications in RA. Proteome analysis of the synovial tissue
is promising to give further understanding on the pathogenesis of joint diseases [65].
Although all the biomarkers listed above are good indicators of RA, factors such as the pres‐
ence of other diseases like osteoporosis, some variations in gene composition and tissue con‐
tent of some of the biomarkers as well as increased physical activities have been found to
change biomarker concentration significantly [12]. Other factors affecting marker level in
mediums includes the diurnal and day-to-day activity; the level of some markers has been
shown to be higher in the morning compared to the evenings. It has been found that mark‐
ers are more abundant in serum samples taken early in the morning before breakfast than
the samples taken after eating. Variation has also been found to occur due to eating and cal‐
cium intake assay precision has also been affected by handling, collecting and storing sam‐
ples/specimens inappropriately [63]. Better and novel biomarkers are being discovered
using proteomic techniques and these are described in section 3. There are a number of
ways that biomarker measurements can aid in the development and evaluation of novel
treatments. Biomarkers provide information for dosing and minimize differences in inter in‐
dividual response to treatment as the assessment of benefit and risk is the goal of develop‐
ing all therapeutic interventions [39]. It has been suggested that proteins, being
‘surrogates‘ for the dynamic biology in organisms, are the macromolecules of choice for bio‐
fluid biomarkers [51]. Hence, a range of proteomics techniques have been applied to the dis‐
covery of novel candidate protein biomarkers [66].
3. Proteins and proteomics techniques in biomarker discovery
Proteomics is the study of protein expression, structure and function directed towards the
characterization of the entire protein complement of a cell, tissue or organism [67]. Proteome
analysis supports the determination of protein expression levels and hence monitors cellular
processes [11]. Protein expression analysis in biological samples is of utmost importance to
identify and monitor biomarkers for the progression of RA and its therapeutic endpoint as
well as providing insight into mechanisms of the disease [68]. Differentially expressed pro‐
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teins and potential biomarkers of RA can be discovered using various proteomic techniques
and has been applied to investigation the dynamic proteome of autoimmune diseases [66,
67, 69]. Once potential protein biomarkers have been identified, their development into di‐
agnostic (or other) tests of clinical usefulness require significant effort and few if any bio‐
markers of clinical utility have emerged from proteomics. Reasons include significant
limitations in the proteomics technologies used for biomarker discovery and challenges
faced in their subsequent validation [70, 71].
One of the major issues to have emerged is the realisation that single protein biomarkers are
unlikely to yield sufficient sensitivity and specificity. However, whilst there is much talk of
multiplexed panels of markers, the application of appropriate statistical tests to the develop‐
ment of such a panel remains relatively poorly understood and applied. Furthermore, whilst
much discovery of biomarkers has been undertaken on tissues and cells, an effective diag‐
nostic assay may require measurement in a readily accessible patient sample such as serum
or synovial fluid. Another major bottleneck has rested in the lack of opportunities or capa‐
bilities to continue the process of biomarker development to progressing them to clinical
utility – a domain of translational research. The biomarker development is the step between
biomarker discovery and confirmation [51]. Different strategies have been used in proteo‐
mics to identify various biomarkers of diseases. These proteomic strategies involve separa‐
tion, analysis and detection of complex protein mixtures.
Historically  gel-based  proteomic  techniques  were  the  tool  of  choice  to  resolve  complex
protein mixtures followed by mass spectrometry (MS) to detect differences in protein ex‐
pression patterns between normal and diseased samples. While gel-based proteomic tech‐
niques  have lost  favor  within  proteomic  research groups due to  its  limitations,  MS has
remained  at  the  forefront  of  proteomic  biomarker  discovery  experiments  coupled  to
more gel-free techniques.
3.1. Gel based proteomics
Pre-separation of target proteins is highly essential in proteomics and many proteomic tech‐
niques accomplishes this with the aid of one- or two-dimensional electrophoresis [72].
One-dimensional sodium dodecyl polyacrlamide gel electrophoresis (1D-SDS PAGE) is a
gel-based method that involves separating proteins on a 1D- SDS Polyacrylamide gel where‐
by the proteins are separated solely based on molecular weight. The bands of the gel are ex‐
cised and subjected to proteolytic digestion ready for analysis by MS. Identified proteins are
used to provide a nonredundant list and the data from samples run in different gel lanes are
compared. This is a good and powerful method for small or medium sized biomarker dis‐
covery studies [72].
Two-dimensional gel electrophoresis (2-DE) is used to separate complex protein mixtures
based  on  their  isoelectric  points  (pI)  and  molecular  weights.  2-DE  is  one  of  the  most
powerful  techniques  for  separating  entire  proteomes  and  was  developed  in  1975  by
O’Farrell [73] and since has been developed further [74]. In the first dimension called iso‐
electric focusing (IEF), proteins are separated based on their (pI). Proteins are amphoteric
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substances and therefore can either be negatively or positively charged depending on the
pH of  their  environment.  During IEF proteins  are  separated along thin  strips  of  polya‐
crylamide gel containing an immobilized pH gradient (IPG). As an electric current is ap‐
plied to the IPG strip during IEF, proteins move through the strip until they reach their
pI i.e. where they no longer have a net charge. In the second dimension the IPG strip is
placed horizontally along the top of a large polyacrylamide gel and proteins are separat‐
ed based on molecular weight whereby smaller proteins will move faster through the gel
than larger ones [51, 67]. Proteins separated by 2-DE can then be visualized by a number
of  staining techniques.  The individual  gel  ‘spots’  may be excised from the gel,  digested
with proteases and the resulting peptides analysed by MS [51].  However,  accuracy and
reproducibility are concerns in this type of experiments [75].
Two- dimensional in gel electrophoresis (2D-DIGE) is an improvement in the use of gel-
based methods for protein quantitation and detection. It has the ability to co-detect several
samples on the same 2DE gel, hence eliminating gel-to-gel variation [75]. In 2D-DIGE ex‐
periments, ester cyanine dyes are used to label proteins prior to 2-DE. The advantage of us‐
ing these dyes is that they are size and charge matched and so ensure negligible shift during
first and second dimensions. Each cyanine dye has different excitation emission spectra al‐
lowing different samples to be run within the same gel and allows the inclusion of an inter‐
nal standard on each gel. 2-DIGE alleviates the pattern reproducibility problem but not the
other problems associated with 2-DE [75].
In  general,  biomarker  discovery  experiments  using  gel-based  methods  have  been  diffi‐
cult  due  to  the  inherent  limitations  of  the  methodologies.  Firstly,  the  hydrophobic,  in‐
soluble  nature  of  membrane  and  membrane  associated  proteins  make  them
incompatible  with the aqueous nature of  the second dimension in 2-DE and so are sig‐
nificantly  underrepresented  in  gel-based  studies  [51].  Invariably,  due  to  the  low  dy‐
namic  range  of  the  gel-method,  the  most  abundant  soluble  proteins  are  best
represented  and  detected  in  2-DE  studies.  Even  with  advances  in  IEF  and  staining
technologies  2-DE gels  are  notoriously difficult  to  reproduce [75].
Today, proteomic studies have moved away from gel-based techniques and now use gel-
free proteomic techniques.
3.2. Mass spectrometry-based proteomics (gel free proteomics)
MS–based proteomics has been used for the global analysis of protein composition, mod‐
ifications  and dynamics  and  this  involves  three  core  experimental  steps;  (i)  protein  ex‐
traction which can be followed by sample fractionation (ii)  enzymatic digestion and (iii)
quantitative and qualitative analysis  using MS [76].  For the analysis  of  complex protein
mixtures, two MS based approaches are used; functional proteomics and expression pro‐
teomics. Functional proteomics also known as the top-down approach involves maintain‐
ing the native structure of the protein and gaining functional information on the protein.
However, a major disadvantage of intact protein analysis is that it does not directly pro‐
vide a sequence-based identification as there are a number of  proteins with close given
masses. Expression proteomics also known as the bottom-up approach involves the dena‐
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turation  of  proteins,  and  using  subsequent  MS  analysis  of  resulting  peptides  to  deter‐
mine quantitative changes in the abundance of proteins under different conditions [77].
By definition,  a  MS consists  of  an ion source,  a  mass analyser  that  measures  the mass-
to-charge  ratio  (m/z)  of  the  ionized  analytes  and  a  detector  that  registers  the  number
of  ions  at  each  m/z  value  [77].  The  primary  methods  of  ionization  in  MS  are  electro‐
spray  ionisation  (ESI),  matrix-assisted  laser  desorption/ionisation  (MALDI)  or  the  sur‐
face-enhanced  laser  desorption  ionisation  (SELDI).  Mass  analysers  could  be  the  SELDI
time-of-flight  (often  used  for  intact/whole  protein  analysis),  MALDI  time-of-flight,  mul‐
tiple  stage  quadrupole-time-of-flight  or  the  quadrupole  ion  trap  (often  used  for  se‐
quence-based  identification)  [58].  MS  has  solved  the  problem  of  identifying  proteins
resolved  by  2D gel  and  other  methods  and has  also  been  used  to  successfully  analyse
complex  protein  mixtures  [58].  Data  from  Gel  LC/MS  often  correlates  with  the  data
generated  during  protein  assay  development  with  the  multiple  reaction  monitoring
method  (MRM)  [51].  The  main  decision  when  carrying  out  gel-  free  based  methods  is
whether to  label  proteins or  not.
Protein  labeling methods include;  (i)  SILAC-stable  isotope labeling with  amino acids  in
cell  culture  for  metabolically  labeled  protein  studies.  In  this  technique,  non-radioactive
heavy  isotopic  forms  of  the  amino  acids  are  metabolically  incorporated  into  the  cellu‐
lar  proteins  while  cells  are  growing  allowing  the  identification  of  cell  surface  proteins
by  MS [2],  ii)  ICAT-isotope  coded affinity  tag  is  used  to  label  proteins  after  extraction
from  biological  samples,  (iii)  iTRAQ-isotope  tags  for  relative  and  absolute  quantitation
and (iv)  TMT- tandem mass tag for  studies involving peptides derived from proteolyti‐
cally  digested  biosamples.  Different  peptides  resulting  from  different  samples  are  la‐
beled  with  different  tags  or  no  tags.  This  allows  different  peptides  from  different
samples  to  be  mixed  together  for  mass  spectrometry  assay.  This  proteomic  technique
is  good  for  studies  involving  small  number  of  samples  up  to  eight  that  can  be  easily
mixed together  for  analysis  [51].
Label-free  detection methods  for  biomarker  discovery are  simpler  and faster  [2].  Exam‐
ples include label-free mass spectrometry (MS) and multi-dimensional liquid chromatog‐
raphy-Mass  spectrometry  (LC-MS).  LC-MS  is  an  analytical  proteomic  technique  that
measures the mass–to-charge (m/z)  of  peptide ions based on their  motion in an electric
or  magnetic  field.  This  technique is  used to  identify,  characterize  and quantify  proteins
based on the mono-isotopic mass of a peptide rather than the average mass of a peptide
[67].  Quantitation  is  achieved  by  aligning  the  LC-MS  data  and  carrying  out  statistical
analysis  across  the  samples.  Differentially  expressed  peptides/protein  are  further  ana‐
lysed  by  MS  for  identification  [51].  This  method  is  good  for  large  biosamples.  Protein
identification  is  dependent  on  the  quality  and  quantity  of  fractionation.  For  more  than
two decades, reverse phase chromatography has been successfully used for peptide sepa‐
rations  and it  plays  a  key  role  in  protein  characterisation  and identification.  Routinely,
peptide separation coupled on-line to tandem mass spectrometry equipped with electro‐
spray ionisation has  been used for  peptide  sequence analysis;  this  has  been application
and sample dependent [67]. Label free proteomics is a good method as it focuses on dif‐
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ferential  expression of  proteins  across  groups.  However,  it  has  long time lines  [51].  Ex‐
amples of mass spectrometry techniques used to achieve this include the nanoflow liquid
chromatography-tandem  mass  spectrometry  (nanoLC-MS/MS)  and  matrix-assisted  laser
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) along with oth‐
er techniques that involve immunocapture platforms of reverse phase protein assays [30].
3.3. Overview of RA biomarker discovery study using mass spectrometry
The main objective of a protein biomarker discovery study is to identify proteins whose lev‐
els are significantly altered in response to some state or conditions such as treatment, dis‐
ease state, mutation, etc.[51]. This technique has also been found to give insight to different
signaling pathways, has improved the discovery of new therapeutic targets, and has been
used to indicate response to and the duration of treatment. The three major steps in the
study of protein biomarkers are discovery, assay development and validation (testing) [51].
A biomarker discovery experiment produces a list of candidate biomarker; the presence and
level of which must be eventually verified in the samples [78].
In RA, biomarker discovery requires identification and quantitation of proteins in the sera,
synovial fluid/tissue of RA patients. These proteins exhibit diverse physico-chemical proper‐
ties [79]. The biomarker discovery in RA using MS is promising to reveal biomarkers capa‐
ble of predicting and/monitor disease activity, joint damage and therapeutic response in
order to minimize expense and toxicity [17]. To accomplish this, early and better prognostic
markers are required[13]. The steps involved in protein biomarker discovery experiment us‐
ing proteomic techniques are as highlighted below.
• Sample collection and storage -This is the most crucial step in proteomics study. Quality
samples are difficult to obtain and there are no means to test the quality of proteins in dif‐
ferent samples. Suggestions include limiting the time of exposure of samples to room
temperature, keeping samples frozen at -80°C as changes in protein are known to occur
very quickly. Collection of serum or plasma from patients should also be carried out fol‐
lowing standard operating procedures (SOP) for plasma collection [51].
• Sample preparation -This is the second crucial step in sample analysis. Sample prepara‐
tion involves the disruption of cellular matrix as homogeneity of samples is essential; sol‐
ubilization of proteins for example in detergents; fractionation of the complex protein
mixture due to the diverse abundance of proteins in the mixture, depleting the most
abundant proteins-albumin, IgG; protein digestion into peptides for MS analysis using
trypsin; removal of nonprotein/nonpeptide molecules for some sample types such as the
synovial fluid and urine. Methods of removing the interfering molecules include electro‐
phoresis through polyacrylamide gel or solid phase extraction (SPE) [51].
• Sample assay -MS has been successfully used to analyse the differential patterns of pro‐
tein and peptide expression in patient biospecimen. This is a high throughput approach
used to assay for millions of peptides [30, 69]. Protein quantitation can be achieved by rel‐
ative or absolute quantitation either by measuring the chromatogram peak area or spec‐
tral counting [51]. Potential biomarkers can be identified from differentially expressed
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proteins among different groups of samples from a proteomic discovery experiment with
the aid of statistical analysis. The acquisition of knowledge on the function of the discov‐
ered potential biomarkers is the main goal of all proteomic research. This is achieved with
the aid of external databases and the literature to know the involvement of each protein
biomarker in different pathways and processes depending on the location of the protein
in the cell [67].
• Statistical  analysis  -  Different  software  tools  are  available  for  differential  analysis  of
proteomic  data.  Usually  the  differential  analysis  between  diseased/healthy  materials,
mutants/wild  type  species,  treated/control  samples  is  the  best  approach  to  study
changes in protein expression levels. However, studies have shown that it is rare that
proteins are either absent or present but they are in most cases up or down regulated
in different samples. Hence, there is a need for a precise and confident analysis of the
quantitative  changes  [67].  The  type  and amount  of  statistical  analysis  depend on the
number  of  biological  and  technical  replicates.  Technical  averages  and  variances  are
used to calculate the biological averages and variances. Analytical and technical varia‐
bility and CV (coefficient of variation) should ideally be less than 10% while biological
variation may be high [51]. Across groups, fold change calculations are done to identi‐
fy  differentially  expressed  proteins.  Although,  arbitrary  cut-offs  are  used  looking  at
the data and this is usually 1.5- or 2- folds change. For three or more biological repli‐
cates,  pvalue  (t-test)  and/or  false  discovery  rates  (FDR)  are  calculated  for  the  data
analyses with cut-offs typically p<0.05 and FDR<20% considered significant respective‐
ly.  Multivariate  analysis  such as  hierarchical  clustering,  principal  component  analysis
and other statistical programs are used for data analysis [51].
3.4. Verification and validation of protein biomarkers in RA
After the discovery phase of biomarkers using proteomic techniques, there is a need to con‐
firm the biomarkers [51]. Verification is the paradigm shift from unbiased discovery experi‐
ments to targeted, hypothesis-driven methods [78]. It is necessary to reliably identify and
reproducibly quantify a potential protein biomarker of interest over multiple samples before
establishing its value as a protein biomarker [68]. There is a need to prove the functions of
the potential biomarkers discovered by a second entirely independent analysis method.
Western blotting and multiple reaction monitoring (MRM) methods are often used for this
task [67]. LC-MS/MS using MRM is gaining acceptance as the primary analytical tool for
quantitation of small molecule biomarkers in biological fluids. This is the quantitation of
proteins using proteolytic digestion followed by MRM quantitation of unique peptides to
the protein of interest [52]. Peptides with analytical or technical variance >20% are not suita‐
ble for a multiple reaction monitoring (MRM) assay [51]. A complete set of analytical sam‐
ples with quality controls and standards are used for validation [52].
Analytical or technical validation is known as verification and this process confirms the as‐
say performance characteristics as well as the required optimal conditions that will give re‐
producible and accurate data. The behaviour of a marker within and between populations
gives the clinical and biological validation [30].
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The procedures taking place after the development and optimization of bioanalytical proce‐
dures is known as validation. The word validation is broad and has been described as the
process of linking a biomarker to clinical or behavioral endpoints [30]. These are aimed to
show that the method is ‘‘fit for purpose’’; and that the procedure is reproducible and relia‐
ble for its intended use. The fundamental parameters involved include accuracy, selectivity,
sensitivity, stability, reproducibility, precision as well as effectiveness of results. [52, 55].
This process of reproducibly quantifying multiple proteins in complex backgrounds over
large cohort of patients’ specimen is highly important in biomarker research [80]. Without
verification and validation of biomarkers, they cannot be used as drug response marker(s) in
clinical practice [30].
There are two common types of assays developed to verify and validate the proteins of in‐
terest. These are the antibody-based assays and the MS-based assays. Both approaches can
be complementary [51]. To develop the protein biomarkers discovered are some proteomic
methods discussed below:
1. Antibody based assays - autoantigen microarrays for the characterisation of antibody
responses, reverse phase protein array studies to analyze phosphoproteins, antibody ar‐
ray technologies to profile cytokines and other biomolecules (e.g western immunoblot
assay, enzyme-linked immunosorbent assay –ELISA, platform specific assays such as
luminex); flow cytometric analysis of phosphoproteins. However, each has their limita‐
tions. Antibody-based assays are highly sensitive, has medium to high specificity, low
multiplexing capability (1-10 proteins), assay development is time consuming and ex‐
pensive, and it has a low success rate as it is difficult to find a pair of antibodies with
high specificity [51, 79, 80].
2. Mass spectrometry based assays- Peptide multiple reaction monitoring (MRM) assays
have emerged as an alternative to affinity-based measurement of proteins [80]. This is
a targeted proteomic method where the mass spectrometer is directed to monitor spe‐
cific  peptides for  the proteins (biomarkers)  of  interest.  This  method involves a  pro‐
tein list and sample type for the assay, selection of unique peptides to the proteins of
interest, selection of fragment ions of the peptide detectable by the mass spectrome‐
ter,  tuning the mass spectrometer to look for the peptides and fragment ions in the
samples  (first  for  individual  peptides  and  then  multiplexed  for  multiple  peptide/
fragments ions for each protein), testing and selection of best peptides for the assay,
as well as checking for technical,  analytical and biological variability using different
samples  [51].  Quantitation  is  achieved  in  MRM  assays  from  the  peak  areas  of  the
fragment  ions  for  each  peptide.  Results  are  refined to  get  the  final  list  of  peptides
and product ions. The refined final list can then be used to test samples for absolute
or relative quantitation comparing values across samples. For relative quantitation, a
sample is chosen as the reference to which other samples are compared while abso‐
lute  quantitation of  protein  concentration involves  labeled and unlabeled standards
for each peptides; calibration curves constructed from labeled peptide standards are
used for peptide quantitation [51]. MRM has a high accuracy, high throughput, sup‐
ports lower detection limits for peptides and supports the measurement of multiple
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proteotypic  peptides  and efforts  are  ongoing to  improve the  development  of  MRM
assay softwares, precision, accuracy and robustness [80]. MS based assays have a me‐
dium  sensitivity,  high  specificity,  high  multiplexing  capability  (ability  to  quantify
multiple proteins in parallel),  takes a shorter period of time to develop assays com‐
pared to the antibody-based assays, has a high success rate and it is not as expensive
as the antibody-based assay (cost- efficiency).  It  is highly reproducible across differ‐
ent instrument platforms and laboratories and has the potential to bridge the gap be‐
tween generating candidate list and their clinical use [51, 80].
It has been predicted that the use of MRM protein assay will increase the number of validat‐
ed medically important protein biomarkers. MRM can provide both relative and absolute
quantitation of peptides like the antibody-based assay. MRM assays has three major advan‐
tages over the antibody based assay i) High specificity for the protein of interest or its iso‐
form; ii)short time lines for assay development and iii) high multiplexing of the assay to
include 25 proteins or more in a single assay [51].
The detection level of proteins using the MRM method depends greatly on the detection of
the protein in a previous biomarker discovery experiment using the GeLC/MS or label free
LC/MS/MS. Other proteins selected as potential biomarkers based on literature review or
other experiments such as transcriptomics may likely exist in low abundance in the samples
of interest. If need be, these protein can be boosted using different enrichment strategies[51].
Important to the development of a successful MRM protein assay is the detection of frag‐
ment ions that are well separated and sufficient data points obtained for each peak. In a typ‐
ical MRM assay, the separation of peptides are based on the retention time in the liquid
chromatography (LC) as well as their mass/charge (m/z) while the peak areas for the frag‐
ment ions for each peptide is used for the quantitative analysis [51].
Novel biomarkers discovered, verified and validated with proteomics are critical in the de‐
velopment of targeted compounds thereby directing rational treatment to patients. In many
autoimmune diseases, studies are underway to define the inflammatory proteome, disease
proteome, vascular proteome and other subsets of the pathologic environment. Potential bi‐
omarkers when verified and biologically validated are promising to lead to the selection of
individuals most likely to benefit from treatment. MRM protein assay developed may be
used routinely for testing biological samples [30, 51].
Using different proteomic techniques, a number of potential RA protein biomarkers are un‐
der study. These includes serum amyloid A [57]; S100 family of calcium binding proteins
found to regulate joint inflammation and cartilage in arthritis [56] and many more as listed
in Table 2. None of the available proteomic methods has emerged as the best for all proteins
biomarker discovery studies. Each method has their pros and cons. The success of proteomic
studies depend on sample quality, the technical variability of the method as well as the
depth of protein analysis. The best platform for proteomic studies depends on factors such
as the number of available samples, the timeline for completion of study and the funds
available for the study [51].
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E-FABP=Epidermal fatty acid binding protein, PRDX=Peroxiredoxin; GRP78/BiP=Glucose related protein precursor;
TXNDC5=Thioredoxin domain-containing protein 5; MnSOD=Manganese superoxide dismutase; MRP = Myeloid relat‐
ed protein; CRP= C-reactive protein; SOD= Superoxide dismutase,GAPDH= Glyceraldehyde 3-phosphate dehydrogen‐
ase, ENOA= enolase, NGAL= d neutrophil gelatinase-associated lipocalin TG2= Tissue transglutaminase 2.
Table 2. A review on inflammatory arthritis associated proteins and mass spectrometry techniques used for
identification. IEF=Ion exchange chromatography; 2D-DIGE=Two dimensional- differential in gel electrophoresis; ESI-
MS=Electrospray ionisation mass spectrometry; 2-DE=Two dimensional gel electrophoresis; MALDI-TOF-MS=Matrix-
assisted laser desorption ionisation time-of-flight mass spectrometry; SELDI-TOF-MS=Surface-enhanced laser
desorption ionisation time-of-flight mass spectrometry; IP=Immunoprecipitation; ID=Immunodepletion; SEC=Size
exclusion chromatography; LC=Liquid chromatography; HPLC=High performance liquid chromatography;
MRM=Multiple reaction monitoring; LTQ-FT-ICR=Ion trap-Fourier Transform mass spectrometer.
3.5. Clinical utility of protein biomarkers in RA
The ultimate aim of RA treatment is to achieve and sustain remission but current targets
include the suppression of disease activity, the improvement of functional ability and the
slowing of  joint  damage [90].  Accurate  measurement  of  disease  activity  can be  used in
therapy management  as  it  should  guide  in  ensuring  that  effective  therapies  are  contin‐
ued  and  ineffective  ones  discontinued  [31].  Treatment  response  in  RA  is  a  measure  of
the suppression of  inflammation solely with acute phase response indicators -  CRP and
ESR  or  in  combination  with  clinical  information.  Prognostic  factors  that  may  affect  re‐
sponse or  no response to treatment include the presence of  rheumatoid factor,  rheuma‐
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toid  nodules,  HLA-DR4/sharp  epitope  and  anti-cyclic  citrullinated  peptide  antibodies
although these cannot be used to predict response to therapy. Hence, there is a need for
new biomarkers to predict  response to therapy and to help in preventing long-term ra‐
diographic progression in patients [91].  Validation of new multiplex assay and technolo‐
gies are essential before clinical applications [52].
A number of factors are responsible for the inability of lots of potential protein biomarkers
reaching clinical utility. These factors have made the translation of biomarkers from bench
to bedside difficult [51]. Decision making is one of the main factors for the utility of bio‐
markers hence, there is a need for all stakeholders in the decision to be involved in the bio‐
marker development. Therefore, in addition to biologists, pharmacologists, medical
practitioners in the appropriate fields, analytical experts are needed for the identification
and quantification of potential biomarkers. They should all be involved in the analyses and
optimal use of the data [92, 93]. With different biomarkers at different stages of validation,
clinicians and researchers are finding it difficult to make a sense of it all [80].
3.6. Challenges /future of biomarkers and proteomics for inflammatory arthritis
Proteins are difficult molecules to monitor with the first technical issue being the insuffi‐
cient  depth of  the  current  methods in  regards  to  the  broad range (12  orders  of  magni‐
tude) of protein concentrations in biofluids. There are different orders of magnitudes for
the  dynamic  range  of  most  methods  [51].  Another  major  limitation  in  translational  re‐
search particularly in the validation step of protein biomarker include lack of reproduci‐
ble, accurate and sensitive assays for most potential biomarker proteins described in the
literature. However, MRM has been reported to allow reproducible protein quantification
[80]. Technical variability is a key factor that affects the design of experiments in proteo‐
mics.  The  higher  the  technical  variability,  the  higher  the  number  of  technical  replicates
that needs to be done and this is evaluated by comparing data from the replicates of the
same sample.  Comparing the data from the replicate samples,  the correlation coefficient
(R2)  calculated gives an indication on the technical  variability.  R2  >0.9 is  an indicator of
low technical variability, R2 between 0.8 and 0.9 is acceptable and R2 < 0.8 is an indicator
of high technical variability and a biological signal might be difficult with the high tech‐
nical  variability  [51].  Multiplexing assays whereby multiple  analytes  are measured from
the same sample is often used to fully understand the correlation between the biomark‐
ers  and the underlying biological  pathways or  to  investigate  the multiple  potential  bio‐
markers  before  deciding  on  the  decision-making  biomarker.  Variability  that  may  occur
due to limited availability of samples or different separation methods can be minimized
by  multiplexing  assays  on  an  LC-MS/MS  platform.  Flow  cytometry  based  technologies
and  planar–array  technologies  also  have  multiplexing  options.  There  is  a  need  to  vali‐
date  these  new  multiplex  assay  platforms  before  recommending  them  for  clinical  use
[52]. In addition, most proteomic techniques are highly sophisticated to operate and have
high demand for hands-on skills. Good operator knowledge and skill as well as the per‐
formance of the instrument are equally important. Therefore educative programs and tu‐
torial are indispensable in proteomic societies [67].
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The effect of combined therapy on response as well as the knowledge of predictive biomark‐
ers of response is a potential emerging area in inflammatory arthritis, as this will promote
personalised medicine. Future studies should aim at the knowledge and better understand‐
ing of the changes occurring in the synovial tissue prior to and upon administration of anti-
TNF-α. In addition, futher studies on the identification of biomarkers that are down
regulated by TNF-α inhibitors can be another useful therapeutic target.
4. Conclusions
The pace of discovery and development of protein biomarkers of IA is accelerating with the
use of a range of proteomic techniques. Together, these have the opportunity to make a sig‐
nificant impact on the treatment of IA. However, the challenges associated with realising
this potential as well as the progression of new biomarkers to clinical utility are significant.
Targeted therapy through the emerging proteomic  technologies  will  help select  patients
who may be more likely to benefit from personalised medicine and this may bring about
the  clinical  adoption  of  molecular  proteomic  stratification.  Comprehensive  proteomic
profiling and trial-focused endpoint profiling will be critical for development of biomark‐
ers and potential  drug targets.  Proteomics will  also aid the understanding of the poten‐
tial  protein  biomarker  signaling  pathways  to  define  the  preferred  targets  of  molecular
therapy. The discovery and validation of new biomarker signatures will broaden our un‐
derstanding of the disease and may lead to development of new potential drugs for per‐
sonalised medicine in IA.
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